Treatment of idiopathic pulmonary fibrosis

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11690839
SERIAL NO

16494590

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to the treatment of idiopathic pulmonary fibrosis with (a) a phosphodiesterase 4 inhibitor or (b) a phosphodiesterase 4 inhibitor and a second active pharmaceutical ingredient.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TAKEDA PHARMACEUTICAL COMPANY LIMITEDOSAKA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hanauer, Guido Constance, DE 10 54
Hazama, Masatoshi Fujisawa, JP 17 192
Nikam, Sham Fujisawa, JP 12 34

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 4, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 4, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 4, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00